GW Pharma (GWPH) PT Raised to $183 at Oppenheimer Due to Eipidolex Approval and Long-Term Growth Potential
Tweet Send to a Friend
Oppenheimer analyst Esther Rajavelu raised the price target on GW Pharma (NASDAQ: GWPH) to $183.00 (from $166.00) while maintaining an ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
